このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Novavax 過去の業績

過去基準チェック /06

Novavaxの収益は年間平均-23.9%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 40%割合で増加しています。

主要情報

-23.9%

収益成長率

-6.1%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	40.0%
株主資本利益率	n/a
ネット・マージン	-40.0%
前回の決算情報	31 Mar 2024

Recent updates

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

Mar 05

収支内訳

Novavax の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:NVAX 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費
31 Mar 24	997	-399	427
31 Dec 23	984	-545	457
30 Sep 23	1,050	-549	464
30 Jun 23	1,597	-587	479
31 Mar 23	1,359	-1,155	505
31 Dec 22	1,982	-658	489
30 Sep 22	1,847	-1,322	411
30 Jun 22	1,291	-1,476	366
31 Mar 22	1,403	-1,318	331
31 Dec 21	1,146	-1,744	298
30 Sep 21	1,204	-1,075	273
30 Jun 21	1,182	-950	252
31 Mar 21	919	-615	196
31 Dec 20	476	-418	143
30 Sep 20	205	-273	92
30 Jun 20	50	-93	43
31 Mar 20	18	-115	35
31 Dec 19	19	-133	34
30 Sep 19	16	-150	35
30 Jun 19	21	-177	36
31 Mar 19	29	-182	34
31 Dec 18	34	-185	34
30 Sep 18	39	-186	34
30 Jun 18	39	-186	34
31 Mar 18	35	-186	34
31 Dec 17	31	-184	34
30 Sep 17	26	-190	34
30 Jun 17	21	-212	40
31 Mar 17	17	-247	45
31 Dec 16	15	-280	47
30 Sep 16	16	-302	47
30 Jun 16	19	-269	43
31 Mar 16	31	-210	36
31 Dec 15	36	-157	31
30 Sep 15	37	-110	27
30 Jun 15	39	-96	23
31 Mar 15	33	-94	21
31 Dec 14	31	-83	20
30 Sep 14	33	-65	18
30 Jun 14	29	-61	17
31 Mar 14	25	-56	15
31 Dec 13	21	-52	15
30 Sep 13	17	-46	13
30 Jun 13	18	-38	11

質の高い収益: NVAXは現在利益が出ていません。

利益率の向上: NVAXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: NVAXは利益が出ておらず、過去 5 年間で損失は年間23.9%の割合で増加しています。

成長の加速: NVAXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: NVAXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: NVAXの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Novavax 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Recent updates

Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

Price target increased by 13% to US$21.60

President of Research & Development recently sold US$384k worth of stock

Consensus revenue estimates increase by 13%

President of Research & Development notifies of intention to sell stock

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Consensus EPS estimates upgraded to US$0.55 loss

New minor risk - Profitability

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss

President of Research & Development exercised options and sold US$14k worth of stock

Consensus estimates of losses per share improve by 28%

Price target decreased by 20% to US$15.40

Novavax: Another Day Older And Deeper In

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Consensus EPS estimates upgraded to US$0.39 loss, revenue downgraded

New minor risk - Share price stability

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director exercised options and sold US$171k worth of stock

Price target increased by 15% to US$23.25

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

No longer forecast to breakeven

New major risk - Shareholder dilution

Price target increased by 11% to US$24.50

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Consensus estimates of losses per share improve by 11%

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 12%

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

Consensus estimates of losses per share improve by 24%

New minor risk - Profitability

New major risk - Share price stability

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Consensus EPS estimates fall by 35%

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Forecast to breakeven in 2025

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 16% to US$39.33

Consensus EPS estimates upgraded to US$4.96 loss, revenue downgraded

Consensus revenue estimates decrease by 25%

過去基準チェック /06